A share price of Akero Therapeutics Inc [AKRO] is currently trading at $49.56, up 1.93%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AKRO shares have gain 4.36% over the last week, with a monthly amount drifted -3.80%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on August 04, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $76. Previously, BofA Securities upgraded its rating to Buy on January 30, 2025, and elevated its price target to $63. On January 27, 2025, H.C. Wainwright reiterated its Buy rating and revised its price target to $72 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $65 on November 18, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on September 19, 2023, and assigned it a price target of $69. In a note dated August 28, 2023, UBS initiated an Buy rating and provided a target price of $83 on this stock.
Akero Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $21.34 and $58.40. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $49.56 at the most recent close of the market. An investor can expect a potential drop of -7.18% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.32 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Akero Therapeutics Inc [NASDAQ:AKRO] is 16.80. Further, the Quick Ratio stands at 16.80, while the Cash Ratio is 4.38.
Transactions by insiders
Recent insider trading involved Yale Catriona, Chief Development Officer, that happened on Jul 16 ’25 when 10000.0 shares were sold. President and CEO, Cheng Andrew completed a deal on Jul 10 ’25 to sell 30000.0 shares. Meanwhile, Chief Scientific Officer Rolph Timothy sold 12500.0 shares on Jul 07 ’25.
